The median AUC of the BRCA1 mutant type cancer cell lines was smaller than that of the wild-type, indicating that an FLT3 inhibitor (sunitinib) has potential therapeutic effects for hereditary breast cancer and ovarian cancer with a BRCA1 mutation. This evidence concerns the gene FLT3 and breast cancer.